Report cover image

Global Neuroendocrine Carcinoma Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 198 Pages
SKU # APRC20561298

Description

Summary

According to APO Research, The global Neuroendocrine Carcinoma market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Neuroendocrine Carcinoma include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Neuroendocrine Carcinoma, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neuroendocrine Carcinoma, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuroendocrine Carcinoma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Carcinoma revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neuroendocrine Carcinoma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Neuroendocrine Carcinoma revenue, projected growth trends, production technology, application and end-user industry.

Neuroendocrine Carcinoma Segment by Company

Teva
Novartis
Pfizer
Abbvie
Valeant
Mateon
Lexicon
Jubilant
Ipsen
F.Hoffmann-La Roche
Chiasma
Advanced Accelerator
Neuroendocrine Carcinoma Segment by Type

Somatostatin Analogs
Chemotherapy
Targeted Therapy
Neuroendocrine Carcinoma Segment by Application

Oncology Centres
Clinics
Hospital
Ambulatory Surgery Centres
Neuroendocrine Carcinoma Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Neuroendocrine Carcinoma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Neuroendocrine Carcinoma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Carcinoma revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Neuroendocrine Carcinoma Market by Type
1.2.1 Global Neuroendocrine Carcinoma Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Somatostatin Analogs
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.3 Neuroendocrine Carcinoma Market by Application
1.3.1 Global Neuroendocrine Carcinoma Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Oncology Centres
1.3.3 Clinics
1.3.4 Hospital
1.3.5 Ambulatory Surgery Centres
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Neuroendocrine Carcinoma Market Dynamics
2.1 Neuroendocrine Carcinoma Industry Trends
2.2 Neuroendocrine Carcinoma Industry Drivers
2.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
2.4 Neuroendocrine Carcinoma Industry Restraints
3 Global Growth Perspective
3.1 Global Neuroendocrine Carcinoma Market Perspective (2020-2031)
3.2 Global Neuroendocrine Carcinoma Growth Trends by Region
3.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Neuroendocrine Carcinoma Market Size by Region (2020-2025)
3.2.3 Global Neuroendocrine Carcinoma Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Neuroendocrine Carcinoma Revenue by Players
4.1.1 Global Neuroendocrine Carcinoma Revenue by Players (2020-2025)
4.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2020-2025)
4.1.3 Global Neuroendocrine Carcinoma Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Neuroendocrine Carcinoma Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Neuroendocrine Carcinoma Key Players Headquarters & Area Served
4.4 Global Neuroendocrine Carcinoma Players, Product Type & Application
4.5 Global Neuroendocrine Carcinoma Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Neuroendocrine Carcinoma Market CR5 and HHI
4.6.3 2024 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3
5 Neuroendocrine Carcinoma Market Size by Type
5.1 Global Neuroendocrine Carcinoma Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Neuroendocrine Carcinoma Revenue by Type (2020-2031)
5.3 Global Neuroendocrine Carcinoma Revenue Market Share by Type (2020-2031)
6 Neuroendocrine Carcinoma Market Size by Application
6.1 Global Neuroendocrine Carcinoma Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Neuroendocrine Carcinoma Revenue by Application (2020-2031)
6.3 Global Neuroendocrine Carcinoma Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Teva
7.1.1 Teva Comapny Information
7.1.2 Teva Business Overview
7.1.3 Teva Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
7.1.5 Teva Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Pfizer
7.3.1 Pfizer Comapny Information
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
7.3.5 Pfizer Recent Developments
7.4 Abbvie
7.4.1 Abbvie Comapny Information
7.4.2 Abbvie Business Overview
7.4.3 Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
7.4.5 Abbvie Recent Developments
7.5 Valeant
7.5.1 Valeant Comapny Information
7.5.2 Valeant Business Overview
7.5.3 Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
7.5.5 Valeant Recent Developments
7.6 Mateon
7.6.1 Mateon Comapny Information
7.6.2 Mateon Business Overview
7.6.3 Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
7.6.5 Mateon Recent Developments
7.7 Lexicon
7.7.1 Lexicon Comapny Information
7.7.2 Lexicon Business Overview
7.7.3 Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
7.7.5 Lexicon Recent Developments
7.8 Jubilant
7.8.1 Jubilant Comapny Information
7.8.2 Jubilant Business Overview
7.8.3 Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
7.8.5 Jubilant Recent Developments
7.9 Ipsen
7.9.1 Ipsen Comapny Information
7.9.2 Ipsen Business Overview
7.9.3 Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
7.9.5 Ipsen Recent Developments
7.10 F.Hoffmann-La Roche
7.10.1 F.Hoffmann-La Roche Comapny Information
7.10.2 F.Hoffmann-La Roche Business Overview
7.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
7.10.5 F.Hoffmann-La Roche Recent Developments
7.11 Chiasma
7.11.1 Chiasma Comapny Information
7.11.2 Chiasma Business Overview
7.11.3 Chiasma Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
7.11.5 Chiasma Recent Developments
7.12 Advanced Accelerator
7.12.1 Advanced Accelerator Comapny Information
7.12.2 Advanced Accelerator Business Overview
7.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue and Gross Margin (2020-2025)
7.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
7.12.5 Advanced Accelerator Recent Developments
8 North America
8.1 North America Neuroendocrine Carcinoma Revenue (2020-2031)
8.2 North America Neuroendocrine Carcinoma Revenue by Type (2020-2031)
8.2.1 North America Neuroendocrine Carcinoma Revenue by Type (2020-2025)
8.2.2 North America Neuroendocrine Carcinoma Revenue by Type (2026-2031)
8.3 North America Neuroendocrine Carcinoma Revenue Share by Type (2020-2031)
8.4 North America Neuroendocrine Carcinoma Revenue by Application (2020-2031)
8.4.1 North America Neuroendocrine Carcinoma Revenue by Application (2020-2025)
8.4.2 North America Neuroendocrine Carcinoma Revenue by Application (2026-2031)
8.5 North America Neuroendocrine Carcinoma Revenue Share by Application (2020-2031)
8.6 North America Neuroendocrine Carcinoma Revenue by Country
8.6.1 North America Neuroendocrine Carcinoma Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Neuroendocrine Carcinoma Revenue by Country (2020-2025)
8.6.3 North America Neuroendocrine Carcinoma Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Neuroendocrine Carcinoma Revenue (2020-2031)
9.2 Europe Neuroendocrine Carcinoma Revenue by Type (2020-2031)
9.2.1 Europe Neuroendocrine Carcinoma Revenue by Type (2020-2025)
9.2.2 Europe Neuroendocrine Carcinoma Revenue by Type (2026-2031)
9.3 Europe Neuroendocrine Carcinoma Revenue Share by Type (2020-2031)
9.4 Europe Neuroendocrine Carcinoma Revenue by Application (2020-2031)
9.4.1 Europe Neuroendocrine Carcinoma Revenue by Application (2020-2025)
9.4.2 Europe Neuroendocrine Carcinoma Revenue by Application (2026-2031)
9.5 Europe Neuroendocrine Carcinoma Revenue Share by Application (2020-2031)
9.6 Europe Neuroendocrine Carcinoma Revenue by Country
9.6.1 Europe Neuroendocrine Carcinoma Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Neuroendocrine Carcinoma Revenue by Country (2020-2025)
9.6.3 Europe Neuroendocrine Carcinoma Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Neuroendocrine Carcinoma Revenue (2020-2031)
10.2 China Neuroendocrine Carcinoma Revenue by Type (2020-2031)
10.2.1 China Neuroendocrine Carcinoma Revenue by Type (2020-2025)
10.2.2 China Neuroendocrine Carcinoma Revenue by Type (2026-2031)
10.3 China Neuroendocrine Carcinoma Revenue Share by Type (2020-2031)
10.4 China Neuroendocrine Carcinoma Revenue by Application (2020-2031)
10.4.1 China Neuroendocrine Carcinoma Revenue by Application (2020-2025)
10.4.2 China Neuroendocrine Carcinoma Revenue by Application (2026-2031)
10.5 China Neuroendocrine Carcinoma Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Neuroendocrine Carcinoma Revenue (2020-2031)
11.2 Asia Neuroendocrine Carcinoma Revenue by Type (2020-2031)
11.2.1 Asia Neuroendocrine Carcinoma Revenue by Type (2020-2025)
11.2.2 Asia Neuroendocrine Carcinoma Revenue by Type (2026-2031)
11.3 Asia Neuroendocrine Carcinoma Revenue Share by Type (2020-2031)
11.4 Asia Neuroendocrine Carcinoma Revenue by Application (2020-2031)
11.4.1 Asia Neuroendocrine Carcinoma Revenue by Application (2020-2025)
11.4.2 Asia Neuroendocrine Carcinoma Revenue by Application (2026-2031)
11.5 Asia Neuroendocrine Carcinoma Revenue Share by Application (2020-2031)
11.6 Asia Neuroendocrine Carcinoma Revenue by Country
11.6.1 Asia Neuroendocrine Carcinoma Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Neuroendocrine Carcinoma Revenue by Country (2020-2025)
11.6.3 Asia Neuroendocrine Carcinoma Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Neuroendocrine Carcinoma Revenue (2020-2031)
12.2 SAMEA Neuroendocrine Carcinoma Revenue by Type (2020-2031)
12.2.1 SAMEA Neuroendocrine Carcinoma Revenue by Type (2020-2025)
12.2.2 SAMEA Neuroendocrine Carcinoma Revenue by Type (2026-2031)
12.3 SAMEA Neuroendocrine Carcinoma Revenue Share by Type (2020-2031)
12.4 SAMEA Neuroendocrine Carcinoma Revenue by Application (2020-2031)
12.4.1 SAMEA Neuroendocrine Carcinoma Revenue by Application (2020-2025)
12.4.2 SAMEA Neuroendocrine Carcinoma Revenue by Application (2026-2031)
12.5 SAMEA Neuroendocrine Carcinoma Revenue Share by Application (2020-2031)
12.6 SAMEA Neuroendocrine Carcinoma Revenue by Country
12.6.1 SAMEA Neuroendocrine Carcinoma Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Neuroendocrine Carcinoma Revenue by Country (2020-2025)
12.6.3 SAMEA Neuroendocrine Carcinoma Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.